The future of the global poliomyelitis vaccine market looks promising with opportunities in the VAPP, VDPV markets.
- Within the type category, oral poliomyelitis vaccine is expected to witness higher growth over the forecast period due to growing demand for easy-to-administer and needle-free vaccination options is boosting oral polio vaccine use.
- Within the application category, VDPV is expected to witness the higher growth due to rising concerns over VDPV outbreaks are driving demand for targeted vaccination strategies.
- In terms of regions, North America is expected to witness the highest growth over the forecast period due to excellent immunization systems and ongoing polio surveillance programs.
Emerging Trends in Poliomyelitis Vaccine Market
The poliomyelitis vaccine market moves toward routine immunization and readiness for outbreaks and vaccine switches. During 2025-2027, procurement will favor the novel oral poliovirus vaccine, as well as increased capacity for IPV and novel delivery techniques for reaching children. Lucintel anticipates a more regional and data-driven supply chain.- Sustainability: By 2025, eradication programs begin to integrate vaccine delivery that also aims to reduce waste and energy expended on the cold chain while implementing shorter repeat campaigns; WHO estimates 14.5 million zero-dose children (2023), demonstrating the coverage gap. Sustainable procurement will impact tenders as donors will demand greater health impact for a lower cost.
- Product Innovation: By the end of 2025, the deployment of nOPV2 continued to expand and more than 1 billion doses of the vaccine were administered by the end of December 2023. IPV and fractional-dose vaccinations will continue to be deployed in conjunction with oral vaccines. Vaccine portfolios that limit vaccine-derived outbreaks will continue to shape national schedules to 2030.
- Digital Monitoring: By 2025, immunization programs will combine electronic registries with microplanning and geospatial technologies and vaccination campaigns will track children through multiple contact points. Better data will help vaccinate zero-dose communities and eliminate missed settlements in the next 3-5 years.
- Regional Supply Chains: In 2025-2027, procurement will favor the ability to manufacture more vaccines through partnerships and regional technology transfers, and more buffer inventories; UNICEF procured over 2 billion vaccine doses in 2023. Regional capacity will help mitigate disruptions and improve negotiating power during outbreaks.
- Automation: Manufacturers are currently using automated inspection, digital batch records, and high-speed filling to automate steps in IPV and oral poliovirus vaccine production. Production sites goal to produce large batch sizes, over 100,000 doses, at a time. Automation of production will create more consistent production and improve the flexibility of production based on demand.
Recent Developments in the Poliomyelitis Vaccine Market
Poliomyelitis vaccine demand will reach a peak until 2027 due to demand shaping activities such as financing outbreaks, pursuing eradication, and product switching. Public agencies remain the primary buyers, and manufacturers continue to build capacity for the novel oral polio vaccine. According to Lucintel, demand will correlate with the intensity and progress of approvals and certifications of campaigns.- Scaling of The Novel Oral Vaccine (nOPV): In partnership with WHO, 1.2 billion doses of nOPV2 against circulating vaccine-derived poliovirus will have been administered by December 2024. This will shift procurement of novel oral vaccines over the next 3-5 years in favor of other genetically stable oral vaccines.
- Financing of Campaigns: Gavi approved its Polio Immunization financing under its 2026-2030 strategy (June 2025) and funding should sufficiently support demand in lower income countries. High funding demand will keep prices low.
- Increasing IPV: UNICEF’s 2025 procurement tender framework ensures large-scale IPV procurement (over 100 million doses). More IPV use will encourage manufacturers of validated capacity to reduce dependence on oral vaccines.
- Sustaining Outbreak Response Contracts: 2024 saw 74 reported cases of wild poliovirus (January 2025 update) and will sustain the Global Polio Eradication Initiative’s rapid-response contracts, buffer stock agreements, and regional production agreements until 2027.
- Technology for Production of Polio Vaccines: During the World Health Assembly (May 2025), discussions on technology transfer for the production of polio vaccines continued between African and Asian producers. Regional fill-finish capacity will improve deliveries and strengthen regional competition from established non-African producers.
Strategic Growth Opportunities in the Poliomyelitis Vaccine Market
Over the course of 2024 to 2026, the market for the poliomyelitis vaccine is expected to grow in a commercial context as eradication campaigns shift towards addressing persistent transmission, routine immunization recovery, and outbreak preparedness. WHO, UNICEF, GPEI and Lucintel note that beyond emergency tenders, there will be a demand for procurement in locations with ongoing coverage gaps, access issues, and vaccine-derived poliovirus threats.- Routine Immunization Recovery: Governments are returning to vaccinate children after a disruption in their vaccination services, creating a consistent demand for IPV and combination products. UNICEF reported an estimated 14.5 million children within this zero-dose population in 2023 (June 2024). For the next 3 to 5 years, incorporating polio doses into primary care will allow procurement to remain more consistent and predictable.
- Outbreak Response Stockpiles: Public health agencies require rapid deployment of vaccine reserves for the post-campaign response to outbreaks of cVDPV2 and wild poliovirus. WHO and its partners have shipped over 1 billion polio vaccine doses in 2024 (January 2025). Commercially, the regional stockpiles will reward suppliers that are able to maintain a high level of surge capacity and short lead times.
- Higher Value IPV Manufacturing: Eradication planning is reducing the use of oral vaccines, meaning that many countries will choose to cover polio through IPV. The 2024-25 Gavi strategy focuses on the introduction and strengthening of inactivated polio vaccine (IPV) EPI schedules (June 2024). Greater IPV coverage is expected to improve profitability for suppliers. Fractional-dose delivery and combination formats will allow suppliers to improve profitability while meeting safety and transition requirements.
- Geographic Expansion: Pakistan, Afghanistan, and parts of Africa will continue to be priority markets. However, other middle-income countries are expected to increase immunization and outbreak response. Africa had 134 cases of cVDPV2 in 2024 (January 2025). Suppliers who partner with organizations that specialize in varying regions will benefit the most when procurement becomes more decentralized.
- 1.2 billion nOPV2 doses prequalified by the WHO by December 2024 should significantly mitigate cost in the long run due to COVID-affected logistics. Temperature stable formulations will enhance temperature stable carriers and enable an overall decreased cold chain length. Significant revenue from established delivery systems should be expected in the future.
Poliomyelitis Vaccine Market Drivers and Challenges
The factors that will have the greatest positive impact on the poliomyelitis vaccine market will be technological, economic, public health, and regulatory forces. Some of the factors are increasing immunization, international campaigns, innovation of vaccines, and procurement services. There are some drivers of the market that will constrain growth such as financing gaps, constraints on supply, and challenges with surveillance of diseases. Through their position on the market, Lucintel shows the trends expected from governments, manufacturers, and the international health community in terms of their investment, accessibility, and market stability.The factors responsible for driving this market include :
- Expansion of Immunization Programs: Immunization programs at the national, regional or international level will drive demand because there is a strong link between immunization and control of the transmission of a disease. In January 2025, the World Health Organization supported the Global Polio Eradication Initiative in over 100 countries. It is expected that most governments will maintain or continue to extend their vaccination programs for the next 3 to 5 years. Because of this, there will also be a sustained demand for polio vaccines.
- Advances in Technology: Innovations in vaccine formulation, stabilization, and delivery methods also improve the usability of polio vaccines. In 2025, the global health community continued to support the introduction of the type 2 version of the novel oral polio vaccine, which should lessen the risk of outbreaks caused by vacuum-derived types 2 polio. Over the next three to five years, improvements may make vaccines easier to administer in remote areas and increase the reliability of the vaccine supply during outbreaks. Other improvements should help counteract logistical bottlenecks and make new vaccines more easily available to the public in combination with inactivated poliovirus vaccines.
- Funding for Global Eradication: The demand for vaccines will remain more predictable in low-income and high-risk countries due to the coordination of procurement and funding. The Global Polio Eradication Initiative continued to implement its 2022-2026 strategy and supported global vaccinations, surveillance, and response to polio outbreaks during the year 2025. Over the next three to five years, it is expected that funding and collective procurement will provide the demand and lead to supply orders that will decrease market volatility and improve access. However, to win government and multilateral contracts, manufacturers will need to provide evidence of both affordable supply and measurable outcomes for public health.
- Increasing Demand for Outbreak Response: Detection of poliovirus circulation leads to the implementation of emergency vaccination campaigns. Public health officials performed environmental surveillance in May 2025 to detect the poliovirus before clinical disease spread. In the next three to five years, increasing surveillance and better laboratory systems will increase the demand for rapidly available vaccines. Although the demand for vaccines due to outbreak response will vary, continued transmission due to insufficient vaccination coverage will drive governments and international organizations to increase their backup inventories, increase the number of vaccination source countries, and strengthen regional vaccination supply systems.
- Efficiency of Manufacturing and Supply Chain: High-standard manufacturing and regional cold-chain distribution will increase availability of vaccines at lower costs. In June 2025, UNICEF and procurement partners committed to reliable delivery of vaccines to support large-scale immunization campaigns. Automation of vaccine manufacturing will allow increased production with a competitive edge in emergency procurement over the next three to five years. Additionally, increased supply chain efficiency will help address the challenge of pandemic vaccine waste and improve the reliability of supply in challenging transportation environments.
The challenges facing this market include:
- Financing and Affordability: The market is over reliant on donor funding and procurement by the public sector. This means the market is subject to reductions in budgets, competing health concerns, and economic instability. International development spending is reviewed by donors and governments and as of July 2025, global health programs are under even more pressure to justify their spending. The next 3-5 years could cause uncertainty in financing and lead to delays in campaigns, decreases in stockpiling, and reduction in vaccine coverage by routine immunization. Manufacturing orders for vaccines will become more unpredictable. Limited fiscal capacity countries may have challenges introducing new vaccines and maintaining cold chain vaccines.
- Manufacturing and Supply: Stringent biological controls, specialized facilities, compliance to regulations, and a dependable supply of raw materials are required to produce the polio vaccine. As of August 2025, global vaccination programs emphasize the need to ensure adequate stockpiles of vaccines for response to outbreaks. Production, limited supplier diversity, and disruption of transportation in the next 3-5 years, may cause regional shortages of vaccines. Long qualification times for new suppliers increase vulnerability to extended production and the qualification for large manufacturing capacity is increased.
- Low Coverage and High Community Barriers: Vaccine hesitancy, misinformation, conflict, population displacement, difficult geography, and inadequate surveillance continue to limit elimination efforts. In September 2025, health agencies continued to conduct supplementary immunization activities to overcome missed routine vaccinations in areas experiencing persistent transmission. It is anticipated that these barriers will sustain the circulation of poliovirus for at least the next 3 to 5 years, despite adequate vaccine supply. Reaching mobile and underserved populations requires community trust, safe and secure access, quality and timely data, and multiple rounds of campaigns, which drive the costs of operational activities and aligning supply and demand.
List of Poliomyelitis Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies poliomyelitis vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the poliomyelitis vaccine market companies profiled in this report include:
- GSK
- Sanofi-Pasteur
- Merck
- Crucell
- China National Biotech Group
Poliomyelitis Vaccine Market by Segment
The study includes a forecast for the global poliomyelitis vaccine market by type, application, and region.Type [Value ($B) from 2019 to 2035]:
- Poliomyelitis Vaccine Ⅰ
- Poliomyelitis Vaccine Ⅱ
- Poliomyelitis Vaccine Ⅲ
- Oral Poliomyelitis Vaccine
Application [Value ($B) from 2019 to 2035]:
- VAPP
- VDPV
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Poliomyelitis Vaccine Market
The pseudorabies virus vaccine market is based on continual development of diseased-control programs, adoption of improved vaccine technology, and commitment to swine biosecurity. From 2025 to 2027, regulatory surveillance and regional manufacturing capacity will be more significant than broad commercial coverage. In its most recent analysis, Lucintel states that country-level policy execution will dictate adoption.- United States: Regulatory efforts will continue to focus on surveillance, import controls, and diagnostic programs to sustain eradication and ensure the virus does not re-enter the system. In 2025, USDA APHIS continued to include pseudorabies among reported diseases affecting swine health. U.S. commercial production of swine was restricted to controlled systems. This system will ensure demand for approved vaccines and diagnostics, as well as herd-level prevention in the next three to five years.
- China: Vaccination efforts continue to be focused on regional eradication and surveillance efforts. Gene- deleted vaccines and companion diagnostics continue to be developed. In 2025, the Ministry of Agriculture and Rural Affairs published its annual priorities for the prevention and control of animal diseases, including pseudorabies. This policy supports the continuous vaccination of farms and the production of differentiated vaccines in the next three to five years.
- Germany: The market continues to be regulated by EU animal health policies and national surveillance, and vaccine use continues to be more oriented toward the management of commercial risk rather than eradication at the national level. In 2025, the Federal Ministry of Food and Agriculture maintained reporting requirements and biosecurity for animal diseases in Germany. This policy will stimulate the demand for vaccines that are traceable and authorized, and are in accordance with the guidelines for surveillance.
- India: The Indian government's progressive commitments to the development of the organized pig sector (including the livestock health programs and veterinary jobs) are attracting greater investment. In 2025, With a budget allocation of ₹4,521 crore to the Department of Animal Husbandry and Dairying, the government has signaled that in the next 3 to 5 years, it seeks to improve institutional pigtail health infrastructure along the lines of strengthening the purchasing of diagnostics and vaccines. While it continues to be regionally managed, pseudorabies may benefit from this new government directive.
- Japan: While Japan is fixed on biosecurity and movement controls as they relate to swine diseases, it is also interested in preparedness. In April 2025, the Japanese Ministry of Agriculture, Forestry, and Fisheries (MAFF) began the implementation of its FY2025 animal health program focused on strengthening border and farm surveillance. This focus of the program will maintain the premium on high quality vaccines and enhance the domestic preparedness in Japan's pork industry, which is characterized by high regulatory standards.
Features of the Global Poliomyelitis Vaccine Market
- Market Size Estimates: poliomyelitis vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: poliomyelitis vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: poliomyelitis vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the poliomyelitis vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the poliomyelitis vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the poliomyelitis vaccine market by type (poliomyelitis vaccine ⅰ, poliomyelitis vaccine ⅱ, poliomyelitis vaccine ⅲ, and oral poliomyelitis vaccine), application (VAPP and VDPV), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- GSK
- Sanofi-Pasteur
- Merck
- Crucell
- China National Biotech Group
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

